Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PAX8 | Q06710 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.48 |
| ▸ | MEN1 | O00255 | 2/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
| ▸ | HTR2A | P28223 | 1/20 | 0.43 |
| ▸ | HTR2C | P28335 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4066208 | 0.82 | ALDH1A1 (0.58) | PAX8ALDH1A1HTR2AHTR2C | |
| SCHEMBL14631627 | 0.69 | MAPT (0.38) | PAX8ALDH1A1KDM4EMAPT | |
| SCHEMBL29050101 | 0.68 | MEN1 (0.61) | PAX8ALDH1A1MEN1KMT2AKDM4E | |
| SCHEMBL2961716 | 0.68 | CNR1 (0.54) | ALDH1A1KDM4EHTR2AHTR2C | |
| SCHEMBL29942151 | 0.68 | CNR1 (0.54) | ALDH1A1KDM4EHTR2AHTR2C | |
| SCHEMBL17559719 | 0.68 | MEN1 (0.65) | PAX8ALDH1A1MEN1KMT2AKDM4E | |
| SCHEMBL28906358 | 0.68 | ESR1 (0.57) | ALDH1A1MEN1KMT2AKDM4EMAPT | |
| SCHEMBL5211637 | 0.67 | ALDH1A1 (0.68) | ALDH1A1KDM4EMAPT | |
| SCHEMBL4875370 | 0.67 | HTR6 (0.70) | ALDH1A1MEN1KMT2AKDM4EMAPT | |
| SCHEMBL28380663 | 0.67 | ALDH1A1 (0.61) | PAX8ALDH1A1MEN1KMT2AMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2033645-A1 | Isoquinoline derivatives and methods of use thereof | Inotek Pharmaceuticals Corporation (US) | 2009-03-11 | — | — | EP | disclosed |
| EP-1603568-A4 | ISOQUINOLINE DERIVATIVES AND METHODS OF USE THEREOF | INOTEK PHARMACEUTICALS CORP (US) | 2009-02-25 | — | — | EP | disclosed |
| US-20080262016-A1 | ISOQUINOLINE DERIVATIVES AND METHODS OF USE THEREOF | INOTEK PHARMACEUTICALS CORPORATION (US) | 2008-10-23 | — | — | US | disclosed |
| US-7393955-B2 | Isoquinoline derivatives and methods of use thereof | INOTEK PHARMACEUTICALS CORPORATION (US) | 2008-07-01 | — | — | US | disclosed |
| EP-1722797-A4 | ISOQUINOLINE DERIVATIVES AND METHODS OF USE THEREOF | INOTEK PHARMACEUTICALS CORP (US) | 2008-03-19 | — | — | EP | disclosed |
| US-7268143-B2 | Isoquinoline derivatives and methods of use thereof | INOTEK PHARMACEUTICALS CORPORATION (US) | 2007-09-11 | — | — | US | disclosed |
| EP-1722797-A1 | ISOQUINOLINE DERIVATIVES AND METHODS OF USE THEREOF | Inotek Pharmaceuticals Corporation (US) | 2006-11-22 | — | — | EP | disclosed |
| US-20060019980-A1 | Methods for treating or preventing erectile dysfunction or urinary incontinence | INOTEK PHARMACEUTICAL, CORP. (US) | 2006-01-26 | — | — | US | disclosed |
| US-20050282848-A1 | Isoquinoline derivatives and methods of use thereof | INOTEK PHARMACEUTICALS CORPORATION (US) | 2005-12-22 | — | — | US | disclosed |
| EP-1603568-A2 | ISOQUINOLINE DERIVATIVES AND METHODS OF USE THEREOF | Inotek Pharmaceuticals Corporation (US) | 2005-12-14 | — | — | EP | disclosed |
| US-6956035-B2 | Isoquinoline derivatives and methods of use thereof | INOTEK PHARMACEUTICALS CORPORATION (US) | 2005-10-18 | — | — | US | disclosed |
| US-20050228007-A1 | Isoquinoline derivatives and methods of use thereof | INOTEK PHARMACEUTICALS CORPORATION | 2005-10-13 | — | — | US | disclosed |
| WO-2005082368-A1 | ISOQUINOLINE DERIVATIVES AND METHODS OF USE THEREOF | INOTEK PHARMACEUTICALS CORPORATION (US) | 2005-09-09 | — | — | WO | disclosed |
| US-20050049270-A1 | Isoquinoline derivatives and methods of use thereof | JAGTAP PRAKASH (US) | 2005-03-03 | — | — | US | disclosed |
| WO-2004078712-A2 | ISOQUINOLINE DERIVATIVES AND METHODS OF USE THEREOF | INOTEK PHARMACEUTICALS CORPORATION (US) | 2004-09-16 | — | — | WO | disclosed |
| US-20040039009-A1 | Isoquinoline derivatives and methods of use thereof | INOTEK PHARMACEUTICALS CORPORATION | 2004-02-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050228007-A1 | Isoquinoline derivatives and methods of use thereof | GLS, PINK1, PARK7 | PAX8 2066/4885ALDH1A1 635/4885MEN1 4630/4885 |
| US-20080262016-A1 | ISOQUINOLINE DERIVATIVES AND METHODS OF USE THEREOF | CYP3A7, CYP3A5, ABCG2 | PAX8 4341/4885ALDH1A1 1165/4885MEN1 2655/4885 |
| US-20060019980-A1 | Methods for treating or preventing erectile dysfunction or urinary incontinence | PDE3A, PDE3B, PDE5A | PAX8 2347/4885ALDH1A1 478/4885MEN1 3084/4885 |
| US-20050282848-A1 | Isoquinoline derivatives and methods of use thereof | CYP3A7, CYP3A5, ABCG2 | PAX8 4341/4885ALDH1A1 1165/4885MEN1 2655/4885 |
| US-20040039009-A1 | Isoquinoline derivatives and methods of use thereof | CYP3A7, CYP3A5, ABCG2 | PAX8 4341/4885ALDH1A1 1165/4885MEN1 2655/4885 |
| US-20050049270-A1 | Isoquinoline derivatives and methods of use thereof | CYP3A7, CYP3A5, ABCG2 | PAX8 4341/4885ALDH1A1 1165/4885MEN1 2655/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.